These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1657503)

  • 21. Histomorphometric analysis of bone in idiopathic hypercalciuria before and after treatment with thiazide.
    Steiniche T; Mosekilde L; Christensen MS; Melsen F
    APMIS; 1989 Apr; 97(4):302-8. PubMed ID: 2719851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
    Reeve J; Meunier PJ; Parsons JA; Bernat M; Bijvoet OL; Courpron P; Edouard C; Klenerman L; Neer RM; Renier JC; Slovik D; Vismans FJ; Potts JT
    Br Med J; 1980 Jun; 280(6228):1340-4. PubMed ID: 6992932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of 1,25-dihydroxycholecalciferol, parathyroid hormone, and thyroxine on trabecular bone remodeling in adult dogs. A histomorphometric study.
    High WB; Capen CC; Black HE
    Am J Pathol; 1981 Dec; 105(3):279-87. PubMed ID: 6895577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol.
    Lund B; Hjorth L; Kjaer I; Reimann I; Friis T; Andersen RB; Sorensen OH
    Lancet; 1975 Dec; 2(7946):1168-71. PubMed ID: 53656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A stochastic analysis of iliac trabecular bone dynamics.
    Reeve J
    Clin Orthop Relat Res; 1986 Dec; (213):264-78. PubMed ID: 3780102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
    Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
    J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis?
    Joffe P; Heaf JG; Jensen C
    Miner Electrolyte Metab; 1996; 22(4):224-33. PubMed ID: 8807626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
    Yao W; Tian XY; Chen J; Setterberg RB; Lundy MW; Chmielzwski P; Froman CA; Jee WS
    J Musculoskelet Neuronal Interact; 2007; 7(2):119-30. PubMed ID: 17627081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in quantitative bone histomorphometry in aging healthy men.
    Clarke BL; Ebeling PR; Jones JD; Wahner HW; O'Fallon WM; Riggs BL; Fitzpatrick LA
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2264-70. PubMed ID: 8964862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis.
    Orwoll ES; McClung MR; Oviatt SK; Recker RR; Weigel RM
    J Bone Miner Res; 1989 Feb; 4(1):81-8. PubMed ID: 2718782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortical and trabecular bone microarchitecture and turnover in alcohol-induced chronic pancreatitis: a histomorphometric study.
    Schnitzler CM; Mesquita JM; Shires R
    J Bone Miner Metab; 2010 Jul; 28(4):456-67. PubMed ID: 20101423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
    Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
    Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
    J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C; Agnusdei D; Gonnelli S
    Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
    Steiniche T
    APMIS Suppl; 1995; 51():1-44. PubMed ID: 7669370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of stanozolol on bone mineral density and bone biomechanical properties of osteoporotic rats.
    Liao JM; Wu T; Li QN; Hu B; Huang LF; Li ZH; Yuan L; Zhong SZ
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1117-20. PubMed ID: 14625163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone loss in response to long-term glucocorticoid therapy.
    LoCascio V; Bonucci E; Imbimbo B; Ballanti P; Adami S; Milani S; Tartarotti D; DellaRocca C
    Bone Miner; 1990 Jan; 8(1):39-51. PubMed ID: 2306553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
    Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
    Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.